The US FDA has accepted the supplemental biologics license application (sBLA) for trastuzumab deruxtecan (T-DXd; Enhertu) ...
A groundbreaking study reveals the potential of alternative donors in bone marrow transplantation, paving the way for improved patient outcomes and innovative practices.
Harpreet Singh, MD, former director of the FDA's Division of Oncology 2 and chief medical officer of Precision for Medicine, discusses the FDA's draft guidance on the use of overall survival (OS) as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback